GCM
CGEM icon

Gladius Capital Management’s Cullinan Oncology CGEM Stock Holding History

Gladius Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,578
Closed -$27.7K – 391
2023
Q2 		$27.7K Sell
2,578
-400
-13% -$4.25K ﹤0.01% 269
2023
Q1 		$30.5K Sell
2,978
-16
-0.5% -$176 ﹤0.01% 284
2022
Q4 		$31.6K Buy
2,994
+240
+9% +$2.92K ﹤0.01% 296
2022
Q3 		$36K Buy
+2,754
New +$37.1K ﹤0.01% 242

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Gladius Capital Management's CGEM Position: Q3 2023 in Review

Gladius Capital Management sold out of Cullinan Oncology (CGEM) in Q3 2023, closing a stake of 2,578 shares — an estimated $27.7K sold.

Gladius Capital Management first reported a position in CGEM in Q3 2022 and held it in 4 quarters. The position peaked at $36K in Q3 2022. 106 funds tracked by Wall St. Rank hold CGEM as of Q3 2023.

  • Gladius Capital Management reported no remaining Cullinan Oncology position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 2,578 Cullinan Oncology shares in Q3 2023, an estimated $27.7K.
  • Gladius Capital Management first reported a position in Cullinan Oncology in Q3 2022 and held it in 4 quarters.
  • Gladius Capital Management's Cullinan Oncology position peaked at $36K in Q3 2022.
  • 106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.